|
|
Effect of Kangdaxin Oral Liquid on oxidative stress in rats with cardiorenal syndrome |
WU Xiang ZHANG Tingting XIONG Shangquan |
Department of Cardiology,Affiliated People′s Hospital of Fujian University of Traditional Chinese Medcine,Fujian Province,Fuzhou 350004,China |
|
|
Abstract Objective To investigate the effect and potential mechanism of Kangdaxin Oral Liquid on cardiorenal syndrome (CRS) rats.Methods Sixty SD rats were randomly divided into 5 groups:sham operation (sham) group,heart failure (HF) group,CRS group,HF+intervention (I) group and CRS+I group.Left ventricular ejection fraction (LVEF)and left ventricular shortening fraction (FS) were measured by cardiac color ultrasound.The levels of serum N-terminal pro-B type natriuretic peptide (NT-proBNP),creatinine (Cr),urea nitrogen (Bun),total antioxidant capacity (TAOC),superoxide dismutase (SOD),malondialdehyde (MDA) were determined by ELISA.Results The FS and LVEF values of rats in HF group,HF+I group,CRS group and CRS+I group were lower than those in sham group,and serum NT-proBNP level was higher than that in sham group,the differences were statistically significant (P<0.05).The FS and LVEF values in HF+I group were higher than those in HF group,and the level of NT-proBNP was lower than that in HF group,the differences were statistically significant (P<0.05).The FS and LVEF values of CRS+I group were higher than those of CRS group,and the level of NT-proBNP was lower than that of CRS group,the differences were statistically significant (P<0.05).The levels of serum Cr and Bun in CRS group and CRS+I group were higher than those in sham group,and the differences were statistically significant (P<0.05).The levels of serum Cr and Bun in CRS+I group were lower than those in CRS group,the differences were statistically significant (P<0.05).Serum TAOC and SOD levels in HF group,HF+I group,CRS group and CRS+I group were lower than those in sham group,while MDA level was higher than that in sham group,the differences were statistically significant (P<0.05).Serum T-AOC and SOD levels in HF+I group were higher than those in HF group,while MDA levels were lower than those in HF group,the differences were statistically significant (P<0.05).Serum T-AOC and SOD levels in CRS+I group were higher than those in CRS group,while MDA levels were lower than those in CRS group,the differences were statistically significant (P<0.05).Conclusion Kangdaxin Oral Liquid may improve cardiac function in rats with cardiorenal syndrome by promoting antioxidant capacity and suppressing oxidative stress.
|
|
|
|
|
[16] |
吴翔,熊尚全,郑峰,等.康达心口服液改善2 型心肾综合征患者心肾功能作用的分析[J].福建医药杂志,2016,38(3):88-90.
|
[1] |
Kumar U,Wettersten N,Garimella PS.Cardiorenal Syndrome:Pathophysiology[J].Cardiol Clin,2019,37(3):251-265.
|
[2] |
Costanzo MR.The Cardiorenal Syndrome in Heart Failure[J].Heart Fail Clin,2020,16(1):81-97.
|
[3] |
Raina R,Nair N,Chakraborty R,et al.An Update on the Pathophysiology and Treatment of Cardiorenal Syndrome[J].Cardiol Res,2020,11(2):76-88.
|
[4] |
Jentzer JC,Bihorac A,Brusca SB,et al.Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council.Contemporary Management of Severe?Acute Kidney Injury and Refractory Cardiorenal Syndrome:JACC Council Perspectives[J].J Am Coll Cardiol,2020,76(9):1084-1101.
|
[5] |
Hatamizadeh P.Cardiorenal Syndrome:An Important Subject in Nephrocardiology[J].Cardiol Clin,2021,39(3):455-469.
|
[6] |
吴翔,宫玉榕,杨直,等.康达心对心肾综合征大鼠心脏保护效应的机制研究[J].中国临床药理学杂志,2019,35(7):643-646.
|
[7] |
Rossi M,Johnson DW,Morrison M,et al.SYNbiotics Easing Renal failure by improving Gut microbiologY (SYNERGY):a protocol of placebo-controlled randomised cross-over trial[J].BMC Nephrol,2019,4(15):106-112.
|
[8] |
Goffredo G,Barone R,Di Terlizzi V,et al.Biomarkers in Cardiorenal Syndrome[J].J Clin Med,2021,10(15):3433.
|
[9] |
Zhao Y,Wang C,Hong X,et al.Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome[J].Kidney Int,2019,95(4):815-829.
|
[10] |
Gembillo G,Visconti L,Giusti MA,et al.Cardiorenal Syndrome:New Pathways and Novel Biomarkers[J].Biomolecules,2021,11(11):1581-1588.
|
[13] |
郑峰,郑伯仁,林超,等.慢性心力衰竭患者基质金属蛋白酶-9 的变化及康达心的影响[J].中国老年保健医学,2012,10(4):57-59.
|
[14] |
吴翔,张婷婷,乔建峰,等.康达心口服液对射血分数保留心力衰竭大鼠心肌纤维化的影响[J].中西医结合心脑血管病杂志,2020,18(24):4149-4151.
|
[15] |
江灵艳.康达心对阳虚水泛型慢性心力衰竭患者GDF-15 的影响及疗效观察[D].福州:福建中医药大学,2020.
|
[11] |
Marsault E,Llorens-Cortes C,Iturrioz X,et al.The apelinergic system:a perspective on challenges and opportunities in cardiovascular and metabolic disorders[J].Ann N Y Acad Sci,2019,1455(1):12-33.
|
[12] |
Cowger JA,Radjef R.Advanced Heart Failure Therapies and Cardiorenal Syndrome[J].Adv Chronic Kidney Dis,2020,25(5):443-453.
|
[17] |
Yenkoyan K,Harutyunyan H,Harutyunyan A.A certain role of SOD/CAT imbalance in pathogenesis of autism spectrum disorders[J].Free Radic Biol Med,2018,1(12):85-95.
|
[18] |
Majidi Z,Hosseinkhani S,Amiri-Dashatan N,et al.Effect of rosiglitazone on circulating malondialdehyde (MDA)level in diabetes based on a systematic review and metaanalysis of eight clinical trials[J].J Investig Med,2021,69(3):697-703.
|
|
|
|